[Antisense drug development].
Funato
Tadao
T
tfunato@hs.med.kyoto-u.ac.jp
Takeda
Mayu
M
D016373:DNA, Antisense; D016503:Drug Delivery Systems; D015195:Drug Design; D018390:Gene Targeting / Q000379:methods*; D030342:Genetic Diseases, Inborn / Q000188:drug therapy / Q000235:genetics; D006678:HIV / Q000235:genetics; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000235:genetics; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics; D011519:Proto-Oncogenes; D012313:RNA / Q000502:physiology; D034622:RNA Interference; D012333:RNA, Messenger / Q000235:genetics*; D013873:Thionucleotides / Q000235:genetics; D014777:Virus Diseases / Q000188:drug therapy / Q000235:genetics
D016373:DNA, Antisense; D012333:RNA, Messenger; D013873:Thionucleotides; D018799:Intercellular Adhesion Molecule-1; D012313:RNA; C408162:oblimersen